Second-line and beyond: treatment options for primary persistent and chronic immune thrombocytopenia

References

• Grimaldi-Bensouda L, Nordon C, Michel M, Viallard J-F, Adoue D, Magy-Bertrand N, Durand J-M, Quittet P, Fain O, Bonnotte B, et al. Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome. Haematologica. 2016;101:1039–1045. doi: 10.3324/haematol.2016.143271.
   PubMed Web of Science ®Google Scholar
• Moulis G, Germain J, Comont T, Brun N, Dingremont C, Castel B, Arista S, Sailler L, Lapeyre-Mestre M, Beyne-Rauzy O, et al. Newly diagnosed immune thrombocytopenia adults: clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort. Am J Hematol. 2017;92:493–500. doi: 10.1002/ajh.24702.
   PubMed Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168–186. doi: 10.1182/blood-2009-12-255992.
   PubMed Web of Science ®Google Scholar
• Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA. American society of hematology. The American society of hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117:4190–4207. doi: 10.1182/blood-2010-08-302984.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386–2393. doi: 10.1182/blood-2008-03-146472.
   PubMed Web of Science ®Google Scholar
• Michel M, Suzan F, Adoue D, Bordessoule D, Marolleau J-P, J-F V, Godeau B. Management of immune thrombocytopenia in adults: a population-based analysis of the French hospital discharge database from 2009 to 2012. Br J Haematol. 2015;170:218–222. doi: 10.1111/bjh.13415.
   PubMed Web of Science ®Google Scholar
• Wang KKW, Charles C, Heddle NM, Arnold E, Molnar L, Arnold DM. Understanding why patients with immune thrombocytopenia are deeply divided on splenectomy. Health Expect. 2014;17:809–817. doi: 10.1111/j.1369-7625.2012.00806.x.
   PubMed Web of Science ®Google Scholar
• Guan Y, Wang S, Xue F, Liu X, Zhang L, Li H, Yang R. Long-term results of splenectomy in adult chronic immune thrombocytopenia. Eur J Haematol. 2017;98:235–241. doi: 10.1111/ejh.2017.98.issue-3.
   PubMed Web of Science ®Google Scholar
• Palandri F, Polverelli N, Catani L, Sollazzo D, Romano M, Levorato M, Vianelli N. The choice of second-line therapy in steroid-resistant immune thrombocytopenia: role of platelet kinetics in a single-centre long-term study. Am J Hematol. 2014;89:1047–1050. doi: 10.1002/ajh.23579.
   PubMed Web of Science ®Google Scholar
• Vianelli N, Palandri F, Polverelli N, Stasi R, Joelsson J, Johansson E, Ruggeri M, Zaja F, Cantoni S, Catucci AE, et al. Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. Haematologica. 2013;98:875–880. doi: 10.3324/haematol.2012.075648.
   PubMed Web of Science ®Google Scholar
• Park YH, Yi HG, Kim CS, Hong J, Park J, Lee JH, Kim HY, Kim HJ, Zang DY, Kim SH, et al. Clinical outcome and predictive factors in the response to splenectomy in elderly patients with primary immune thrombocytopenia: a Multicenter Retrospective Study. Acta Haematol. 2016;135:162–171. doi: 10.1159/000442703.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Porras JR, Escalante F, Pardal E, Sierra M, Garcia-Frade LJ, Redondo S, Arefi M, Aguilar C, Ortega F, de Cabo E, et al. Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia. Eur J Haematol. 2013;91:236–241. doi: 10.1111/ejh.12146.
   PubMed Web of Science ®Google Scholar
• Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004;104:2623–2634. doi: 10.1182/blood-2003-11-3979.
   PubMed Web of Science ®Google Scholar
• Ahmed R, Devasia AJ, Viswabandya A, Lakshmi KM, Abraham A, Karl S, Mathai J, Jacob PM, Abraham D, Srivastava A, et al. Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children : splenectomy in ITP. Ann Hematol. 2016;95:1429–1434. doi: 10.1007/s00277-016-2738-3.
   PubMed Web of Science ®Google Scholar
• Chater C, Terriou L, Duhamel A, Launay D, Chambon JP, Pruvot FR, Rogosnitzky M, Zerbib P. Reemergence of splenectomy for ITP second-line treatment? Ann Surg. 2016;264:772–777. doi: 10.1097/SLA.0000000000001912.
   PubMed Web of Science ®Google Scholar
• Ghanima W, Godeau B, Cines DB, Bussel JB. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood. 2012;120:960–969. doi: 10.1182/blood-2011-12-309153.
   PubMed Web of Science ®Google Scholar
• Wu Z, Zhou J, Pankaj P, Peng B. Laparoscopic splenectomy for immune thrombocytopenia (ITP) patients with platelet counts lower than 1 × 109/L. Int J Hematol. 2011;94:533–538. doi: 10.1007/s12185-011-0962-0.
   PubMed Web of Science ®Google Scholar
• Cai Y, Liu X, Peng B. Should we routinely transfuse platelet for immune thrombocytopenia patients with platelet count less than 10 × 109/L who underwent laparoscopic splenectomy? World J Surg. 2014;38:2267–2272. doi: 10.1007/s00268-014-2560-9.
   PubMed Web of Science ®Google Scholar
• Keidar A, Feldman M, Szold A. Analysis of outcome of laparoscopic splenectomy for idiopathic thrombocytopenic purpura by platelet count. Am J Hematol. 2005;80:95–100. doi: 10.1002/(ISSN)1096-8652.
   PubMed Web of Science ®Google Scholar
• Habermalz B, Sauerland S, Decker G, Delaitre B, Gigot J-F, Leandros E, Lechner K, Rhodes M, Silecchia G, Szold A, et al. Laparoscopic splenectomy: the clinical practice guidelines of the European Association for Endoscopic Surgery (EAES). Surg Endosc. 2008;22:821–848. doi: 10.1007/s00464-007-9735-5.
   PubMed Web of Science ®Google Scholar
• Bulvik S, Winder A, Ben-Tal O, Szold A, Eldor A. High-dose dexamethasone for splenectomy in patients with idiopathic thrombocytopenic purpura. Haemostasis. 1998;28:256–259. doi: 10.1159/000022379.
   PubMedGoogle Scholar
• Godeau B, Caulier MT, Decuypere L, Rose C, Schaeffer A, Bierling P. Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomized trial comparing 0.5 and 1 g/kg b.w. Br J Haematol. 1999;107:716–719.
   PubMed Web of Science ®Google Scholar
• Arnold DM, Jamula E, Heddle NM, Cook RJ, Hsia C, Sholzberg M, Lin Y, Kassis J, Blostein M, Larratt L, et al. Peri-operative eltrombopag or immune globulin for patients with immune thrombocytopaenia (The Bridging ITP Trial): methods and rationale. Thromb Haemost. 2019;119:500–507. doi: 10.1055/s-0038-1677531.
   PubMed Web of Science ®Google Scholar
• Sarpatwari A, Provan D, Erqou S, Sobnack R, David Tai FW, Newland AC. Autologous 111 in-labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United Kingdom ITP registry. Br J Haematol. 2010;151:477–487. doi: 10.1111/j.1365-2141.2010.08377.x.
   PubMed Web of Science ®Google Scholar
• Kazi S, Mckiddie F, Anderson J, Bagot C, Duncan C, Drummond M, Kerr R, Khan M, McColl M, Roddie H, et al. Autologous 111 in-labelled platelet scan as a predictor of splenectomy outcome in ITP. Br J Haematol. 2018. doi: 10.1111/bjh.15236.
   PubMed Web of Science ®Google Scholar
• Thai L-H, Mahévas M, Roudot-Thoraval F, Limal N, Languille L, Dumas G, Khellaf M, Bierling P, Michel M, Godeau B. Long-term complications of splenectomy in adult immune thrombocytopenia. Medicine (Baltimore). 2016;95:e5098. doi: 10.1097/MD.0000000000004864.
   PubMed Web of Science ®Google Scholar
• Boyle S, White RH, Brunson A, Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood. 2013;121:4782–4790. doi: 10.1182/blood-2012-12-467068.
   PubMed Web of Science ®Google Scholar
• Davies JM, Lewis MPN, Wimperis J, Rafi I, Ladhani S, Bolton-Maggs PHB. Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: prepared on behalf of the British committee for standards in haematology by a working party of the haemato-oncology task force: guideline. Br J Haematol. 2011;155:308–317. doi: 10.1111/j.1365-2141.2010.08188.x.
   PubMed Web of Science ®Google Scholar
• Togasaki E, Shimizu N, Nagao Y, Kawajiri-Manako C, Shimizu R, Oshima-Hasegawa N, Muto T, Tsukamoto S, Mitsukawa S, Takeda Y, et al. Long-term efficacy of partial splenic embolization for the treatment of steroid-resistant chronic immune thrombocytopenia. Ann Hematol. 2018;97:655–662. doi: 10.1007/s00277-018-3232-x.
   PubMed Web of Science ®Google Scholar
• Mazzucconi MG, Santoro C, Baldacci E, De Angelis F, Chisini M, Ferrara G, Volpicelli P, Foà R. TPO-RAs in pITP: description of a case series and analysis of predictive factors for response. Eur J Haematol. 2017;98:242–249. doi: 10.1111/ejh.2017.98.issue-3.
   PubMed Web of Science ®Google Scholar
• Wong RSM, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, Bussel JB. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017;130:2527–2536. doi: 10.1182/blood-2017-04-748707.
   PubMed Web of Science ®Google Scholar
• Taylor A, Westwood JP, Laskou F, McGuckin S, Scully M. Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond. Br J Haematol. 2017;177:475–480. doi: 10.1111/bjh.2017.177.issue-3.
   PubMed Web of Science ®Google Scholar
• Mazza P, Minoia C, Melpignano A, Polimeno G, Cascavilla N, Di Renzo N, Specchia G. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a “real life” retrospective multicenter experience of the Rete Ematologica Pugliese (REP). Ann Hematol. 2016;95:239–244. doi: 10.1007/s00277-015-2556-z.
   PubMed Web of Science ®Google Scholar
• Mahévas M, Fain O, Ebbo M, Roudot-Thoraval F, Limal N, Khellaf M, Schleinitz N, Bierling P, Languille L, Godeau B, et al. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Haematol. 2014;165:865–869. doi: 10.1111/bjh.12888.
   PubMed Web of Science ®Google Scholar
• González-López TJ, Pascual C, Álvarez-Román MT, Fernández-Fuertes F, Sánchez-González B, Caparrós I, Jarque I, Mingot-Castellano ME, Hernández-Rivas JA, Martín-Salces M, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol. 2015;90:E40–43. doi: 10.1002/ajh.23900.
   PubMed Web of Science ®Google Scholar
• Newland A, Godeau B, Priego V, Viallard J-F, López Fernández MF, Orejudos A, Eisen M. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. Br J Haematol. 2016;172:262–273. doi: 10.1111/bjh.2016.172.issue-2.
   PubMed Web of Science ®Google Scholar
• Zhang J, Liang Y, Ai Y, Li X, Xie J, Li Y, Zheng W, He R. Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis. PLoS One. 2018;13:e0198504. doi: 10.1371/journal.pone.0198504.
   PubMed Web of Science ®Google Scholar
• Lakhwani S, Perera M, Fernández-Fuertes F, Ríos de Paz MA, Torres M, Raya JM, Hernández MT. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres. Eur J Haematol. 2017;99:372–377. doi: 10.1111/ejh.2017.99.issue-4.
   PubMed Web of Science ®Google Scholar
• Khellaf M, Viallard J-F, Hamidou M, Cheze S, Roudot-Thoraval F, Lefrere F, Fain O, Audia S, Abgrall J-F, Michot J-M, et al. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica. 2013;98:881–887. doi: 10.3324/haematol.2012.074633.
   PubMed Web of Science ®Google Scholar
• González-Porras JR, Mingot-Castellano ME, Andrade MM, Alonso R, Caparrós I, Arratibel MC, Fernández-Fuertes F, Cortti MJ, Pascual C, Sánchez-González B, et al. Use of eltrombopag after romiplostim in primary immune thrombocytopenia. Br J Haematol. 2015;169:111–116. doi: 10.1111/bjh.13266.
   PubMed Web of Science ®Google Scholar
• Michel M, Wasser J, Godeau B, Aledort L, Cooper N, Tomiyama Y, Khellaf M, Wang X. Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopenia. Ann Hematol. 2015;94:1973–1980. doi: 10.1007/s00277-015-2485-x.
   PubMed Web of Science ®Google Scholar
• Cines DB, Gernsheimer T, Wasser J, Godeau B, Provan D, Lyons R, Altomare I, Wang X, Lopez A. Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim. Int J Hematol. 2015;102:259–270. doi: 10.1007/s12185-015-1837-6.
   PubMed Web of Science ®Google Scholar
• Steurer M, Quittet P, Papadaki HA, Selleslag D, Viallard J-F, Kaiafa G, Janssens A, Kozak T, Wadenvik H, Schoonen M, et al. A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice. Eur J Haematol. 2017;98:112–120. doi: 10.1111/ejh.12807.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Giagounidis A, Viallard J-F, Godeau B, Pabinger I, Cines D, Liebman H, Wang X, Woodard P. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials. Eur J Haematol. 2013;91:423–436. doi: 10.1111/ejh.12181.
   PubMedGoogle Scholar
• Weber E, Moulis G, Mahévas M, Guy C, Lioger B, Durieu I, Hunault M, Ramanantsoa M, Royer B, Default A, et al. [Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study]. Rev Med Interne. 2017;38:167–175. doi: 10.1016/j.revmed.2016.09.016.
   PubMed Web of Science ®Google Scholar
• Brynes RK, Wong RSM, Thein MM, Bakshi KK, Burgess P, Theodore D, Orazi A. A 2-year, longitudinal, prospective study of the effects of eltrombopag on bone marrow in patients with chronic immune thrombocytopenia. Acta Haematol. 2017;137:66–72. doi: 10.1159/000452992.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Muus P, Kantarjian H, Lyons RM, Larson RA, Sekeres MA, Becker PS, Orejudos A, Franklin J. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy. Br J Haematol. 2017;178:906–913. doi: 10.1111/bjh.14792.
   PubMed Web of Science ®Google Scholar
• Lambert MP, Witmer CM, Kwiatkowski JL. Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia. Am J Hematol. 2017;92:E88–E91. doi: 10.1002/ajh.24705.
   PubMed Web of Science ®Google Scholar
• Carpenedo M, Cantoni S, Coccini V, Pogliani EM, Cairoli R. Response loss and development of neutralizing antibodies during long-term treatment with romiplostim in patients with immune thrombocytopenia: a case series. Eur J Haematol. 2016;97:101–103. doi: 10.1111/ejh.2016.97.issue-1.
   PubMed Web of Science ®Google Scholar
• Patel VL, Mahévas M, Lee SY, Stasi R, Cunningham-Rundles S, Godeau B, Kanter J, Neufeld E, Taube T, Ramenghi U, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119:5989–5995. doi: 10.1182/blood-2011-10-388512.
   PubMed Web of Science ®Google Scholar
• Khellaf M, Charles-Nelson A, Fain O, Terriou L, Viallard J-F, Cheze S, Graveleau J, Slama B, Audia S, Ebbo M, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood. 2014;124:3228–3236. doi: 10.1182/blood-2014-06-582346.
   PubMed Web of Science ®Google Scholar
• Marangon M, Vianelli N, Palandri F, Mazzucconi MG, Santoro C, Barcellini W, Fattizzo B, Volpetti S, Lucchini E, Polverelli N, et al. Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. Eur J Haematol. 2017;98:371–377. doi: 10.1111/ejh.12839.
   PubMed Web of Science ®Google Scholar
• Zwaginga JJ, van der Holt B, Te Boekhorst PA, Biemond BJ, Levin M-D, van der Griend R, Brand A, Zweegman S, Pruijt HFM, Novotny VMJ, et al. Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients. Haematologica. 2015;100:e90–92. doi: 10.3324/haematol.2014.110213.
   PubMed Web of Science ®Google Scholar
• Reboursiere E, Fouques H, Maigne G, Johnson H, Chantepie S, Gac AC, Reman O, Macro M, Benabed K, Troussard X, et al. Rituximab salvage therapy in adults with immune thrombocytopenia: retrospective study on efficacy and safety profiles. Int J Hematol. 2016;104:85–91. doi: 10.1007/s12185-016-1992-4.
   PubMed Web of Science ®Google Scholar
• Arnold DM, Heddle NM, Carruthers J, Cook DJ, Crowther MA, Meyer RM, Liu Y, Cook RJ, McLeod A, MacEachern JA, et al. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood. 2012;119:1356–1362. doi: 10.1182/blood-2011-10-388512.
   PubMed Web of Science ®Google Scholar
• Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146:25–33. doi: 10.7326/0003-4819-146-1-200701020-00006.
   PubMed Web of Science ®Google Scholar
• Godeau B, Porcher R, Fain O, Lefrère F, Fenaux P, Cheze S, Vekhoff A, Chauveheid M-P, Stirnemann J, Galicier L, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood. 2008;112:999–1004. doi: 10.1182/blood-2008-03-140830.
   PubMed Web of Science ®Google Scholar
• Auger S, Duny Y, Rossi JF, Quittet P. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis. Br J Haematol. 2012;158:386–398. doi: 10.1111/bjh.2012.158.issue-3.
   PubMed Web of Science ®Google Scholar
• Garcia-Chavez J, Majluf-Cruz A, Montiel-Cervantes L, Esparza MG-R, Vela-Ojeda J. Mexican hematology study group. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis. Ann Hematol. 2007;86:871–877. doi: 10.1007/s00277-007-0317-3.
   PubMed Web of Science ®Google Scholar
• Mahévas M, Ebbo M, Audia S, Bonnotte B, Schleinitz N, Durand J-M, Chiche L, Khellaf M, Bierling P, Roudot-Thoraval F, et al. Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia. Am J Hematol. 2013;88:858–861. doi: 10.1002/ajh.23518.
   PubMed Web of Science ®Google Scholar
• Zhang C, Liu H-F, Chen X-H, Gao L, Gao L, Liu Y, Kong P-Y, A-H S, Zhang X. Is splenectomy necessary for immune thrombocytopenic purpura? The role of rituximab in patients with corticosteroid resistance in a single-center experience. Clin Ther. 2014;36:385–388. doi: 10.1016/j.clinthera.2014.01.017.
   PubMed Web of Science ®Google Scholar
• Zaja F, Vianelli N, Volpetti S, Battista ML, Defina M, Palmieri S, Bocchia M, Medeot M, De Luca S, Ferrara F, et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2010;85:329–334. doi: 10.1111/j.1600-0609.2010.01486.x.
   PubMed Web of Science ®Google Scholar
• Hasan A, Michel M, Patel V, Stasi R, Cunningham-Rundles S, Leonard JP, Bussel J. Repeated courses of rituximab in chronic ITP: three different regimens. Am J Hematol. 2009;84:661–665. doi: 10.1002/ajh.v84:10.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Lee CS, Seery C, Imahiyerobo AA, Thompson MV, Catellier D, Turenne IG, Patel VL, Basciano PA, Elstrom RL, et al. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. Haematologica. 2014;99:1264–1271. doi: 10.3324/haematol.2013.103291.
   PubMed Web of Science ®Google Scholar
• Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, Vianelli N, Defina M, Tieghi A, Amadori S, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. 2010;115:2755–2762. doi: 10.1182/blood-2009-12-255992.
   PubMed Web of Science ®Google Scholar
• Chapin J, Lee CS, Zhang H, Zehnder JL, Bussel JB. Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia. Am J Hematol. 2016;91:907–911. doi: 10.1002/ajh.24434.
   PubMed Web of Science ®Google Scholar
• Choi PY-I, Roncolato F, Badoux X, Ramanathan S, Ho S-J, Chong BH. A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). Blood. 2015;126:500–503. doi: 10.1182/blood-2015-03-631937.
   PubMed Web of Science ®Google Scholar
• Levy R, Mahévas M, Galicier L, Boutboul D, Moroch J, Loustau V, Guillaud C, Languille L, Fain O, Bierling P, et al. Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature. Autoimmun Rev. 2014;13:1055–1063. doi: 10.1016/j.autrev.2014.08.036.
   PubMed Web of Science ®Google Scholar
• Vancine-Califani SMC, De Paula EV, Ozelo MC, Orsi FLA, Fabri DR, Annichino-Bizzacchi JM. Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura. Platelets. 2008;19:489–495. doi: 10.1080/09537100802315110.
   PubMed Web of Science ®Google Scholar
• Oo T, Hill QA. Disappointing response to dapsone as second line therapy for primary ITP: a case series. Ann Hematol. 2015;94:1053–1054. doi: 10.1007/s00277-014-2285-8.
   PubMed Web of Science ®Google Scholar
• Estève C, Samson M, Guilhem A, Nicolas B, Leguy-Seguin V, Berthier S, Bonnotte B, Audia S. Efficacy and safety of dapsone as second line therapy for adult immune thrombocytopenia: A retrospective study of 42 patients. PLoS One. 2017;12:e0187296. doi: 10.1371/journal.pone.0187296.
   PubMed Web of Science ®Google Scholar
• Rodrigo C, Gooneratne L. Dapsone for primary immune thrombocytopenia in adults and children: an evidence-based review. J Thromb Haemost. 2013;11:1946–1953. doi: 10.1111/jth.2013.11.issue-11.
   PubMed Web of Science ®Google Scholar
• Godeau B, Durand JM, Roudot-Thoraval F, Tennezé A, Oksenhendler E, Kaplanski G, Schaeffer A, Bierling P. Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases. Br J Haematol. 1997;97:336–339.
   PubMed Web of Science ®Google Scholar
• Zaja F, Marin L, Chiozzotto M, Puglisi S, Volpetti S, Fanin R. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab. Am J Hematol. 2012;87:321–323. doi: 10.1002/ajh.22266.
   PubMed Web of Science ®Google Scholar
• Radaelli F, Calori R, Goldaniga M, Guggiari E, Luciano A. Adult refractory chronic idiopathic thrombocytopenic purpura: can dapsone be proposed as second-line therapy? Br J Haematol. 1999;104:641–642. doi: 10.1046/j.1365-2141.1999.01305.x.
   PubMed Web of Science ®Google Scholar
• Patel AP, Patil AS. Dapsone for immune thrombocytopenic purpura in children and adults. Platelets. 2015;26:164–167. doi: 10.3109/09537104.2014.886677.
   PubMed Web of Science ®Google Scholar
• Damodar S, Viswabandya A, George B, Mathews V, Chandy M, Srivastava A. Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults–a report on 90 patients. Eur J Haematol. 2005;75:328–331. doi: 10.1111/ejh.2005.75.issue-4.
   PubMed Web of Science ®Google Scholar
• Depré F, Aboud N, Mayer B, Salama A. Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: results from a long-term observation in clinical practice. PLoS One. 2018;13:e0198184. doi: 10.1371/journal.pone.0198184.
   PubMed Web of Science ®Google Scholar
• Vesely SK, Perdue JJ, Rizvi MA, Terrell DR, George JN. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review. Ann Intern Med. 2004;140:112–120. doi: 10.7326/0003-4819-140-3-200402030-00012.
   PubMed Web of Science ®Google Scholar
• Weber E, Reynaud Q, Fort R, Durupt S, Cathébras P, Durieu I, Lega J-C. Immunomodulatory treatments for persistent and chronic immune thrombocytopenic purpura: A PRISMA-compliant systematic review and meta-analysis of 28 studies. Medicine (Baltimore). 2017;96:e7534. doi: 10.1097/MD.0000000000007534.
   PubMed Web of Science ®Google Scholar
• Sauvetre G, Mahévas M, Limal N, Guillaud C, Khellaf M, Bierling P, Languille L, Delbos F, Noizat-Pirenne F, Michel M, et al. Cutaneous rash and dapsone-induced hypersensitivity syndrome a common manifestation in adult immune thrombocytopenia. Presentation and outcome in 16 cases. Am J Hematol. 2015;90:E201–202. doi: 10.1002/ajh.24068.
   PubMed Web of Science ®Google Scholar
• Liu W, Gu X, Fu R, Li Y, Lv M, Sun T, Lv C, Liu X, Xue F, Zhang L, et al. The effect of danazol in primary immune thrombocytopenia: an analysis of a large cohort from a single center in China. Clin Appl Thromb Hemost. 2016;22:727–733. doi: 10.1177/1076029615622002.
   PubMed Web of Science ®Google Scholar
• Ahn YS, Harrington WJ, Simon SR, Mylvaganam R, Pall LM, So AG. Danazol for the treatment of idiopathic thrombocytopenic purpura. N Engl J Med. 1983;308:1396–1399. doi: 10.1056/NEJM198306093082306.
   PubMed Web of Science ®Google Scholar
• Maloisel F, Andrès E, Zimmer J, Noel E, Zamfir A, Koumarianou A, Dufour P. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med. 2004;116:590–594. doi: 10.1016/j.amjmed.2003.12.024.
   PubMed Web of Science ®Google Scholar
• Daou S, Federici L, Zimmer J, Maloisel F, Serraj K, Andrès E. Idiopathic thrombocytopenic purpura in elderly patients: a study of 47 cases from a single reference center. Eur J Intern Med. 2008;19:447–451. doi: 10.1016/j.ejim.2007.07.006.
   PubMed Web of Science ®Google Scholar
• Taylor A, Neave L, Solanki S, Westwood JP, Terrinonive I, McGuckin S, Kothari J, Cooper N, Stasi R, Scully M. Mycophenolate mofetil therapy for severe immune thrombocytopenia. Br J Haematol. 2015;171:625–630. doi: 10.1111/bjh.2015.171.issue-4.
   PubMed Web of Science ®Google Scholar
• Cooper N. State of the art - how I manage immune thrombocytopenia. Br J Haematol. 2017;177:39–54. doi: 10.1111/bjh.2017.177.issue-1.
   PubMed Web of Science ®Google Scholar
• Hou M, Peng J, Shi Y, Zhang C, Qin P, Zhao C, Ji X, Wang X, Zhang M. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol. 2003;70:353–357. doi: 10.1034/j.1600-0609.2003.00076.x.
   PubMed Web of Science ®Google Scholar
• Colović M, Suvajdzic N, Colović N, Tomin D, Vidović A, Palibrk V. Mycophenolate mophetil therapy for chronic immune thrombocytopenic purpura resistant to steroids, immunosuppressants, and/or splenectomy in adults. Platelets. 2011;22:153–156. doi: 10.3109/09537104.2010.520372.
   PubMed Web of Science ®Google Scholar
• Provan D, Moss AJ, Newland AC, Bussel JB. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol. 2006;81:19–25. doi: 10.1002/(ISSN)1096-8652.
   PubMed Web of Science ®Google Scholar
• Hoeltzenbein M, Elefant E, Vial T, Finkel-Pekarsky V, Stephens S, Clementi M, Allignol A, Weber-Schoendorfer C, Schaefer C. Teratogenicity of mycophenolate confirmed in a prospective study of the European network of teratology information services. Am J Med Genet A. 2012;158A:588–596. doi: 10.1002/ajmg.a.35223.
   PubMed Web of Science ®Google Scholar
• Engelen W, Verpooten GA, Van der Planken M, Helbert MF, Bosmans JL, De Broe ME. Four cases of red blood cell aplasia in association with the use of mycophenolate mofetil in renal transplant patients. Clin Nephrol. 2003;60:119–124. doi: 10.5414/CNP60119.
   PubMed Web of Science ®Google Scholar
• Quiquandon I, Fenaux P, Caulier MT, Pagniez D, Huart JJ, Bauters F. Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases. Br J Haematol. 1990;74:223–228. doi: 10.1111/j.1365-2141.1990.tb02569.x.
   PubMed Web of Science ®Google Scholar
• Caplan SN, Berkman EM. Immunosuppressive therapy of idiopathic thrombocytopenic purpura. Med Clin North Am. 1976;60:971–986. doi: 10.1016/S0025-7125(16)31843-0.
   PubMed Web of Science ®Google Scholar
• Pizzuto J, Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: multicentric trial of the cooperative Latin American group on hemostasis and thrombosis. Blood. 1984;64:1179–1183.
   PubMed Web of Science ®Google Scholar
• Emilia G, Morselli M, Luppi M, Longo G, Marasca R, Gandini G, Ferrara L, D’Apollo N, Potenza L, Bertesi M, et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood. 2002;99:1482–1485. doi: 10.1182/blood.V99.4.1482.
   PubMed Web of Science ®Google Scholar
• Kappers-Klunne MC, Van’t Veer MB. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol. 2001;114:121–125. doi: 10.1046/j.1365-2141.2001.02893.x.
   PubMed Web of Science ®Google Scholar
• Choudhary DR, Naithani R, Mahapatra M, Kumar R, Mishra P, Saxena R. Efficacy of cyclosporine as a single agent therapy in chronic idiopathic thrombocytopenic purpura. Haematologica. 2008;93:e61–62. discussion e63. doi: 10.3324/haematol.13481.
   PubMedGoogle Scholar
• Li J, Wang Z, Dai L, Cao L, Su J, Zhu M, Yu Z, Bai X, Ruan C. Effects of rapamycin combined with low dose prednisone in patients with chronic immune thrombocytopenia. Clin Dev Immunol. 2013;2013:548085. doi: 10.1155/2013/657424.
   PubMedGoogle Scholar
• Emilia G, Luppi M, Morselli M, Forghieri F, Potenza L, Torelli G. A possible role for low-dose cyclosporine in refractory immune thrombocytopenic purpura. Haematologica. 2008;93:1113–1115. doi: 10.3324/haematol.12741.
   PubMed Web of Science ®Google Scholar
• Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood. 1995;85:351–358.
   PubMed Web of Science ®Google Scholar
• Verlin M, Laros RK, Penner JA. Treatment of refractory thrombocytopenic purpura with cyclophosphamine. Am J Hematol. 1976;1:97–104. doi: 10.1002/ajh.2830010111.
   PubMed Web of Science ®Google Scholar
• Park YH, Yi HG, Lee MH, Kim CS, Lim JH. Clinical efficacy and tolerability of vincristine in splenectomized patients with refractory or relapsed immune thrombocytopenia: a retrospective single-center study. Int J Hematol. 2016;103:180–188. doi: 10.1007/s12185-015-1903-0.
   PubMed Web of Science ®Google Scholar
• Stirnemann J, Kaddouri N, Khellaf M, Morin A-S, Prendki V, Michel M, Mekinian A, Bierling P, Fenaux P, Godeau B, et al. Vincristine efficacy and safety in treating immune thrombocytopenia: a retrospective study of 35 patients. Eur J Haematol. 2016;96:269–275. doi: 10.1111/ejh.12586.
   PubMed Web of Science ®Google Scholar
• Facon T, Caulier MT, Wattel E, Jouet JP, Bauters F, Fenaux P. A randomized trial comparing vinblastine in slow infusion and by bolus i.v. injection in idiopathic thrombocytopenic purpura: a report on 42 patients. Br J Haematol. 1994;86:678–680. doi: 10.1111/j.1365-2141.1994.tb04810.x.
   PubMed Web of Science ®Google Scholar
• Sikorska A, Słomkowski M, Marlanka K, Konopka L, Górski T. The use of vinca alkaloids in adult patients with refractory chronic idiopathic thrombocytopenia. Clin Lab Haematol. 2004;26:407–411.
   PubMedGoogle Scholar
• Marmont AM, Damasio EE. Clinical experiences with cytotoxic immunosuppressive treatment of idiopathic thrombocytopenic purpura. Acta Haematol. 1971;46:74–91. doi: 10.1159/000208563.
   PubMed Web of Science ®Google Scholar
• Szczepanik AB, Sikorska A, Slomkowski M, Konopka L. The use of vinca alkaloids in preparation for splenectomy of corticosteroid refractory chronic immune thrombocytopenic purpura patients. Int J Lab Hematol. 2007;29:347–351. doi: 10.1111/j.1365-2257.2006.00891.x.
   PubMed Web of Science ®Google Scholar
• Khellaf M, Chabrol A, Mahevas M, Roudot-Thoraval F, Limal N, Languille L, Bierling P, Michel M, Godeau B. Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies. Am J Hematol. 2014;89:194–198. doi: 10.1002/ajh.23579.
   PubMed Web of Science ®Google Scholar
• Mohammadpour F, Kargar M, Hadjibabaie M. The role of hydroxychloroquine as a steroid-sparing agent in the treatment of immune thrombocytopenia: a review of the literature. J Res Pharm Pract. 2018;7:4–12.
   PubMed Web of Science ®Google Scholar
• Arnal C, Piette J, Léone J, Taillan B, Hachulla E, Roudot-Thoraval F, Papo T, Schaeffer A, Bierling P, Godeau B. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol. 2002;29:75–83.
   PubMed Web of Science ®Google Scholar
• Tsumoto C, Tominaga K, Okazaki H, Tanigawa T, Yamagami H, Watanabe K, Nakao T, Koh K, Watanabe T, Fujiwara Y, et al. Long-term efficacy of helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura: 7-year follow-up prospective study. Ann Hematol. 2009;88:789–793. doi: 10.1007/s00277-008-0667-5.
   PubMed Web of Science ®Google Scholar
• Emilia G, Luppi M, Zucchini P, Morselli M, Potenza L, Forghieri F, Volzone F, Jovic G, Leonardi G, Donelli A, et al. Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles. Blood. 2007;110:3833–3841. doi: 10.1182/blood-2006-12-063222.
   PubMed Web of Science ®Google Scholar
• Campuzano-Maya G. Proof of an association between helicobacter pylori and idiopathic thrombocytopenic purpura in Latin America. Helicobacter. 2007;12:265–273. doi: 10.1111/hel.2007.12.issue-3.
   PubMed Web of Science ®Google Scholar
• Stasi R, Sarpatwari A, Segal JB, Osborn J, Evangelista ML, Cooper N, Provan D, Newland A, Amadori S, Bussel JB. Effects of eradication of helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood. 2009;113:1231–1240. doi: 10.1182/blood-2008-03-146472.
   PubMed Web of Science ®Google Scholar
• Kim H, Lee W-S, Lee K-H, Bae SH, Kim MK, Joo Y-D, Zang DY, Jo J-C, Lee SM, Lee J-H, et al. Efficacy of helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenia patients with moderate thrombocytopenia. Ann Hematol. 2015;94:739–746. doi: 10.1007/s00277-014-2268-9.
   PubMed Web of Science ®Google Scholar
• Arnold DM, Bernotas A, Nazi I, Stasi R, Kuwana M, Liu Y, Kelton JG, Crowther MA. Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. Haematologica. 2009;94:850–856. doi: 10.3324/haematol.2008.005348.
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Kobayashi T, Yamashita T, Ohashi K, Sakamaki H, Akiyama H. Eight-year follow-up of patients with immune thrombocytopenic purpura related to H. pyloriinfection. Platelets. 2011;22:61–64. doi: 10.3109/09537104.2010.515272.
   PubMed Web of Science ®Google Scholar
• Rostami N, Keshtkar-Jahromi M, Rahnavardi M, Keshtkar-Jahromi M, Esfahani FS. Effect of eradication of helicobacter pylori on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura: a controlled trial. Am J Hematol. 2008;83:376–381. doi: 10.1002/(ISSN)1096-8652.
   PubMed Web of Science ®Google Scholar
• Mahévas M, Michel M, Godeau B. How we manage immune thrombocytopenia in the elderly. Br J Haematol. 2016;173:844–856. doi: 10.1111/bjh.2016.173.issue-6.
   PubMed Web of Science ®Google Scholar
• Thanarajasingam G, Vaidya R, Erie A, Wolanskyj AP. Accessory splenectomy for refractory immune thrombocytopenic purpura. Am J Hematol. 2011;86:520–523. doi: 10.1002/ajh.v86.6.
   PubMed Web of Science ®Google Scholar
• Mahévas M, Gerfaud-Valentin M, Moulis G, Terriou L, Audia S, Guenin S, Le Guenno G, Salles G, Lambotte O, Limal N, et al. Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia. Blood. 2016;128:1625–1630. doi: 10.1182/blood-2016-06-724161.
   PubMed Web of Science ®Google Scholar